ライフサイエンスコーパス: hematopoietic neoplasm

1 Health Organization (WHO) classification of hematopoietic neoplasms.

2 ty has been implicated in the development of hematopoietic neoplasms.

3 5-mC and 5-hmC patterns are common events in hematopoietic neoplasms.

4 tion, and, ultimately, to HSC exhaustion and hematopoietic neoplasms.

5 re syndromes, myelodysplastic syndromes, and hematopoietic neoplasms.

6 romosomal translocation is a common theme in hematopoietic neoplasms.

7 mors, has not been fully elucidated in human hematopoietic neoplasms.

8 and communicate about mouse models of human hematopoietic neoplasms.

9 nationally recognized for their expertise in hematopoietic neoplasms.

10 e classification of lymphoid and nonlymphoid hematopoietic neoplasms.

11 ctivation is a prominent oncogenic driver of hematopoietic neoplasms.

12 this mechanism has been described mostly in hematopoietic neoplasms.

13 mors, has not been fully elucidated in human hematopoietic neoplasms.

14 l models of localized and disseminated human hematopoietic neoplasms.

15 herefore, seems to be a progression event in hematopoietic neoplasms.

16 or (ER) gene, is frequently altered in human hematopoietic neoplasms.

17 7)Lu-DOTATATE: 8 patients (2.9%) developed a hematopoietic neoplasm (4 MDS, 1 AML, 1 MPN, and 2 MDS/M

18 delineated as early as 3 months post-TBI for hematopoietic neoplasms, 6 months for solid neoplasms, a

19 ASopathy characterized by the development of hematopoietic neoplasms and abnormalities affecting the

20 be an important step in the genesis of human hematopoietic neoplasms and might be a useful molecular

21 Cells from hematopoietic neoplasms appear in this limited sample to

22 The expected number of hematopoietic neoplasms based on The Netherlands Cancer

23 eukemia (BCR-ABL1(+) B-ALL) is an aggressive hematopoietic neoplasm characterized by a block in diffe

24 Mastocytosis is a hematopoietic neoplasm characterized by expansion of KIT

25 Systemic mastocytosis (SM) is a KIT-driven hematopoietic neoplasm characterized by the excessive ac

26 clones with somatic variants associated with hematopoietic neoplasms exist within the blood or bone m

27 on in both conditions and also occurs in the hematopoietic neoplasm hairy cell leukemia (HCL).

28 enotypic, and molecular features of a unique hematopoietic neoplasm in these mice.

29 MYC is an important oncogene in hematopoietic neoplasms in humans, yet the mechanism by

30 hat the critical inactivation event in these hematopoietic neoplasms is elimination of p19(Arf), and

31 The development of hematopoietic neoplasms is often associated with mutatio

32 Tempol reduced the incidence of hematopoietic neoplasms (lymphomas) in both strains, whe

33 ands Cancer Registry, the expected number of hematopoietic neoplasms (MDS, AML, MPN, and MDS/MPN) was

34 It is proposed here that nonlymphoid hematopoietic neoplasms of mice be classified in 4 broad

35 ficacy of existing drugs in treating defined hematopoietic neoplasms, paired with promising new data

36 iseases and neoplasms (MPN), a collection of hematopoietic neoplasms regarded as preleukemic, thereby

37 d apoptosis and therefore clinical trials in hematopoietic neoplasms should be of high priority.

38 y that VEGF may play a role in the growth of hematopoietic neoplasms such as multiple myeloma through

39 ears to be gaining a place in the therapy of hematopoietic neoplasms, such as non-Hodgkin's lymphoma,

40 rge B-cell lymphoma (DLBCL) is an aggressive hematopoietic neoplasm that affects humans as well as do

41 ized the need for a classification of murine hematopoietic neoplasms that would allow investigators t

42 The relative risk for developing a hematopoietic neoplasm was 2.7.

43 ility, and the development of transplantable hematopoietic neoplasms with myeloproliferation.

44 rative neoplasms (MPNs) are a set of chronic hematopoietic neoplasms with overlapping clinical and mo

45 M) and mast cell leukemia (MCL) are advanced hematopoietic neoplasms with poor prognosis.